|
Last
Update:
June 13, 2016
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader\
-
Enrollment into
open-label phase of TDF2 PrEP Study, Botswana, 2013
L. Chirwa, A. Taylor, T. Williams, et al
Abstract
-
An analysis of cost and health outcomes associated with
tenofovir/emtricitabine and abacavir/lamivudine in combination with
efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV‑1
infection in the United Kingdom
E. Wilkins, M. Fisher, A.J. Brogan, S.E. Talbird
Abstract
-
Tenofovir and
emtricitabine pharmacokinetics in plasma
and saliva following a single dose of TDF 600mg/FTC 400mg: implications for
on demand PrEP (ANRS Ipergay)
J. Fonsart, B. Loze, S. Morel, et al
Abstract
|
XIX International AIDS Conference
|
-
Pre-exposure
prophylaxis (PrEP) for preventing HIV in high-risk individuals: a
meta-analysis
C.I. Okwundu, O. Uthman
Abstract
-
The incidence of the
hypertriglyceridemic waist phenotype in a randomized prospective comparison
between atazanavir/ritonavir (ATV/r) and lopinavir/ritonavir (LPV/r) each in
combination with tenofovir DF/emtricitabine (TDF/FTC) in antiretroviral naive
HIV
G. Moyle, W. Hu, R. Wang, et al
Abstract
- Effects of
raltegravir (RAL) combined with tenofovir (TDF) and emtricitabine (FTC) on
body shape, bone density and lipids in HIV+ African Americans initiating
therapy: metabolic outcomes of the UNC-REAL study
D. Wohl, L. Young, W. Hyslop, et al
Abstract
-
The role of
community engagement in FEM-PrEP
S. Kirkendale, M. Ratlhagana, P. Omullo,
et al
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
Switching from
abacavir/lamivudine to tenofovirDF/emtricitabine reduces biomarkers of
inflammation
O. Alozie, R. Prosser, K. Huppler Hullsiek,
et al
Abstract
-
Delayed emergence
of HIV-1 variants resistant to 4'-ethnyl-2-fluoro-2'-deoxyadenosine (EFdA):
comparative sequential passage study with tenofovir, emtricitabine and
festinavir
K. Maeda, D. Desai, H. Nakata,, H. Mitsuya
Abstract
-
Demographic, behavioural and clinical characteristics of women enrolled into
the VOICE (Vaginal and Oral Interventions
to Prevent HIV) study (MTN-003)
J. Marrazzo, VOICE (MTN 003) Study Team
Abstract
|
Tenofovir Disoproxil Fumarate/Emtricitabine
(Truvada)
Conference Citations |
|
Truvada Main Page
Main
New/Newsworthy